We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

224 hedge funds and large institutions have $2.54B invested in Sage Therapeutics in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 72 increasing their positions, 76 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

30% more call options, than puts

Call options by funds: $21.6M | Put options by funds: $16.6M

14% more capital invested

Capital invested by funds: $2.22B → $2.54B (+$321M)

6% more funds holding

Funds holding: 212 → 224 (+12)

1.99% more ownership

Funds ownership: 88.53% → 90.53% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 76

Holders
224
Holders Change
+12
Holders Change %
+5.66%
% of All Funds
3.52%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
72
Reduced
76
Closed
18
Calls
$21.6M
Puts
$16.6M
Net Calls
+$4.98M
Net Calls Change
-$3.09M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$84.9M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$32.3M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$31.7M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$29.5M
5
JP Morgan Chase
JP Morgan Chase
New York
+$15.8M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$41.2M
2
Marshall Wace
Marshall Wace
United Kingdom
-$30.5M
3
BlackRock
BlackRock
New York
-$25.2M
4
State Street
State Street
Massachusetts
-$21.7M
5
Goldman Sachs
Goldman Sachs
New York
-$21.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
76
Walleye Capital
New York
$2.57M +$2.71M +54,561 New
Wells Fargo
77
Wells Fargo
California
$2.56M +$159K +3,194 +6%
EIP
78
Easterly Investment Partners
Massachusetts
$2.4M -$1.47M -29,524 -37%
SAM
79
Simplify Asset Management
Nevada
$2.35M – – –
State of Wisconsin Investment Board
80
State of Wisconsin Investment Board
Wisconsin
$2.32M -$100 -2 -0%
State of New Jersey Common Pension Fund D
81
State of New Jersey Common Pension Fund D
New Jersey
$2.28M -$330K -6,624 -12%
BNP Paribas Financial Markets
82
BNP Paribas Financial Markets
France
$2.21M -$1.23M -24,704 -34%
Two Sigma Advisers
83
Two Sigma Advisers
New York
$2.07M -$4.36M -87,700 -67%
AA
84
ALPS Advisors
Colorado
$2.07M +$228K +4,585 +12%
Victory Capital Management
85
Victory Capital Management
Texas
$1.98M +$882K +17,733 +73%
VRS
86
Virginia Retirement Systems
Virginia
$1.93M +$418K +8,400 +26%
PP
87
PDT Partners
New York
$1.91M +$707K +14,211 +54%
UBS AM
88
UBS AM
Illinois
$1.85M – – –
Stifel Financial
89
Stifel Financial
Missouri
$1.81M -$144K -2,887 -7%
First Trust Advisors
90
First Trust Advisors
Illinois
$1.78M +$1.5M +30,064 +387%
Cambridge Investment Research Advisors
91
Cambridge Investment Research Advisors
Iowa
$1.67M -$33.1K -666 -2%
E
92
Ergoteles
New York
$1.66M +$420K +8,440 +31%
Assenagon Asset Management
93
Assenagon Asset Management
Luxembourg
$1.53M -$3.54M -71,126 -69%
Mirae Asset Global Investments
94
Mirae Asset Global Investments
South Korea
$1.46M -$82.5K -1,659 -5%
Ensign Peak Advisors
95
Ensign Peak Advisors
Utah
$1.46M – – –
Susquehanna International Group
96
Susquehanna International Group
Pennsylvania
$1.44M -$5.49M -110,284 -78%
EAM
97
Erste Asset Management
Austria
$1.34M – – –
MIM
98
MetLife Investment Management
New Jersey
$1.3M +$27.8K +558 +2%
EP
99
Edgestream Partners
New Jersey
$1.29M +$1.36M +27,349 New
Janus Henderson Group
100
Janus Henderson Group
United Kingdom
$1.23M -$19.5M -392,551 -94%
2 3
4
5 6

SAGE Hedge Fund Activity: Q2 2023 in Review

224 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2023, worth a combined $2.54B — up 14% from $2.22B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new SAGE positions and 18 closed out — a net gain of 13 holders — while 72 added to existing stakes and 76 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $84.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $41.2M.

  • 224 institutional investors held Sage Therapeutics (SAGE) as of Q2 2023, up from 212 in Q1 2023.
  • Funds reported $2.54B of Sage Therapeutics stock for Q2 2023, up 14% quarter-over-quarter.
  • 31 funds opened new Sage Therapeutics positions in Q2 2023 and 18 closed out, a net change of +13 holders.
  • The largest Sage Therapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $84.9M added.
  • The largest Sage Therapeutics seller in Q2 2023 was T. Rowe Price Associates, an estimated $41.2M sold.

Based on aggregated 13F filings for Q2 2023.